Adegramotide/Nelatimotide

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAdegramotide/Nelatimotide
Drug Alias Nameelatipepimut-S + adegramotideadegramotide + nelatimotideNelatimotide/Adegramotidenelatimotide + adegramotideadegrapepimut-S + nelatimotide +[7] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionT lymphocytes stimulantsWilms' Tumour 1 modulators
TargetsWilms' Tumour 1
Therapy Area/IndicationsMyelodysplastic SyndromesFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoston Biomedical IncSumitomo Dainippon Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Pharma America Inc
Inactive CompaniesOsaka UniversitySumitomo Pharmaceuticals Co Ltd
Active IndicationsGlioblastoma
Inactive IndicationsMyelodysplastic SyndromesFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 

Other Information

ATC CodeN/A
Related LinksN/A